A new study from the University of Michigan Health Rogel Cancer Center reveals a connection between the most common type of white blood cells, which act as a first defense in the body's immune system, and a severe complication ...
Jun 3, 2024
0
1
The U.S. Food and Drug Administration on Thursday approved a new drug to treat patients with an advanced form of deadly lung cancer.
May 17, 2024
0
1
How do tumors react to a certain therapeutic approach? Knowing this before the start of a therapy would be of enormous value for people suffering from cancer as well as for the doctors treating them.
May 15, 2024
0
7
Researchers at Texas Children's Cancer Center and the Center for Cell and Gene Therapy at Baylor College of Medicine, Texas Children's Hospital and Houston Methodist have published results of a Phase I clinical trial of a ...
Apr 24, 2024
0
39
The U.S. Food and Drug Administration has approved Abecma (idecabtagene vicleucel) as a personalized CAR T-cell therapy for triple-class exposed relapsed or refractory multiple myeloma.
Apr 10, 2024
0
1
A recent USC study provides new information about why SARS-CoV-2, the virus behind the COVID-19 pandemic, may elicit mild symptoms at first but then, for a subset of patients, turn potentially fatal a week or so after infection. ...
Mar 29, 2024
0
57
Chimeric antigen receptor T cells—CAR T cells for short—are immune cells (T cells) that are taken from the body and genetically modified outside the body in the laboratory using transport vehicles for the genes to be ...
Mar 22, 2024
0
0
In the ever-evolving battle against cancer, immunotherapy presents a turning point. It began with harnessing the body's immune system to fight cancer, a concept rooted more than a century ago but only gaining significant ...
Feb 21, 2024
0
63
Researchers from The University of Texas MD Anderson Cancer Center have reported promising results in a Phase I/II trial of 37 patients with relapsed or refractory B-cell malignancies who were treated with cord blood-derived ...
Jan 18, 2024
0
12
Recent advances in treating multiple myeloma, the second most common blood cancer, and other blood malignancies are providing improved outcomes—and hope—to patients worldwide.
Jan 4, 2024
0
3
